We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Mutation Identified as Genetic Marker for Multiple Sclerosis

By LabMedica International staff writers
Posted on 16 Mar 2015
A mutation in the serine-threonine kinase 11 (STK11) gene, which encodes the enzyme liver kinase b1 (LKB1), was shown to be a risk factor for development of multiple sclerosis (MS).

STK11 gene encodes a member of the serine/threonine kinase family and thereby regulates cell polarity while functioning as a tumor suppressor. More...
Mutations in this gene have been associated with Peutz-Jeghers syndrome, an autosomal dominant disorder characterized by the growth of polyps in the gastrointestinal tract, pigmented macules on the skin and mouth, and other cancerous growths.

A serendipitous conversation led investigators at the University of Illinois at Chicago (USA) to apply advanced DNA sequencing tools to study a family whose female members had a high prevalence for both MS and Peutz-Jeghers syndrome.

Sequence analysis of total DNA from one sister from a family with five daughters suffering from MS identified a single-nucleotide polymorphism (SNP) within STK11 intron 5. This SNP (rs9282860) was then identified by Life Technologies (Carlsbad, CA, USA;) TaqMan polymerase chain reaction (PCR) assays in DNA samples available from two other siblings. Further screening was carried out on samples from 654 relapsing-remitting MS patients, 100 primary progressive MS patients, and 661 controls. Results revealed that the STK11-SNP had increased frequency in all female MS patients versus controls.

The STK11-SNP was not associated with disease duration or onset; however, it was significantly associated with reduced severity. In vitro studies showed that peripheral blood mononuclear cells from members of the family were more sensitive to the mitochondrial inhibitor metformin than cells from MS patients with the non-mutated STK11 allele. Thus, the increased association of SNP rs9282860 in women with MS defined this variant as a genetic risk factor.

"The variant occurs almost twice as often among women with MS as in women without the disease, making it one of the strongest genetic risk factors for MS discovered to date," said senior author Dr. Douglas Feinstein, professor of anesthesiology at the University of Illinois at Chicago. "The STK11 SNP is present in about 7% of the general population. But because far fewer people develop MS, other genetic or non-genetic factors must play a role in the development of the disease."

The report was published in the February 18, 2015, online edition of the journal ASN NEURO.

Related Links:

University of Illinois at Chicago
Life Technologies 



Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
Serological Pipet Controller
PIPETBOY GENIUS
New
Silver Member
Autoimmune Hepatitis Test
LKM-1-Ab ELISA
New
Silver Member
Quality Control Material
Multichem ID-B
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: CellLENS enables the potential precision therapy strategies against specific immune cell populations in the tissue environment (Photo courtesy of MIT)

New AI System Uncovers Hidden Cell Subtypes to Advance Cancer Immunotherapy

To produce effective targeted therapies for cancer, scientists need to isolate the genetic and phenotypic characteristics of cancer cells, both within and across different tumors. These differences significantly... Read more

Pathology

view channel
Image: Micrograph showing the distribution of misfolded proteins in myeloma cells (Photo courtesy of Helmholtz Munich)

Novel Method Tracks Cancer Treatment in Cells Without Dyes or Labels

Multiple myeloma is a blood cancer that affects plasma cells in the bone marrow, leading to abnormal protein production, weakened immunity, and organ damage. Traditional methods for evaluating myeloma... Read more

Technology

view channel
Image: Researchers Dr. Lee Eun Sook and Dr. Lee Jinhyung examine the imprinting equipment used for nanodisk synthesis (Photo courtesy of KRISS)

Multifunctional Nanomaterial Simultaneously Performs Cancer Diagnosis, Treatment, and Immune Activation

Cancer treatments, including surgery, radiation therapy, and chemotherapy, have significant limitations. These treatments not only target cancerous areas but also damage healthy tissues, causing side effects... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.